
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Single application of 2 percent solution clears infection as well as three-day regimen; nonetheless, hyper-, hypopigmentary changes may last for months






